Drug intelligence / Profile preview

MG-O-1509

Development stage: Preclinical
Lead developer: Metagone Biotech
Modality: Small Molecules

Overview

MG-O-1509 is a preclinical drug candidate being developed by Metagone Biotech and Theratocular Biotek for the treatment of tumor-agnostic cancers. It functions as a targeted therapy by inhibiting the phosphorylated Death-Associated Protein Kinase (pDAPK) pathway. DAPK is a calcium/calmodulin-dependent serine/threonine kinase that plays a critical role in regulating cell death mechanisms such as apoptosis and autophagy. By targeting pDAPK, MG-O-1509 aims to address malignancies characterized by specific molecular dysregulation in this pathway, regardless of the tumor's primary site of origin.

Targets

DAPK (Death-associated protein kinase family)

Beyond the preview

Go deeper on MG-O-1509.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG-O-1509.

Explore the full profile